Resource Center
Explore Resource Types
We have housed the technical documents (SDS, COAs, Manuals and more) in a dedicated section.
Explore all All Resources
Filters
Select resource types
Select products & services
Select solutions (2)
Active Filters (2)
Clear All
145 - 153 of 153 Results
Sort by:
Best Match
Whitepaper
Exploring current and future approaches for targeting KRAS
Get the latest insights on KRAS and see how it has switched from being an undruggable to a druggable cancer target
Flyer
Bioanalytical methods for biosimilarity assessment
Working in partnership to develop and qualify assays in the support of the biosimilarity assessment data package.
Application Note
Avoiding biotin interference in AlphaLISA assays
This application note demonstrates the value of using AlphaLISA biotin-free kits to reduce the effects of biotin interference in sample and standard preparations.
Application Note
No-Wash IP1 assays are a powerful readout to characterize compounds modulating the FGFR signaling pathway in cancer drug research
This application note demonstrates that detecting the intracellular accumulation of IP1, mediated by FGFR-dependent activation of PLCγ1, can be a powerful alternative for characterizing compounds that modulate FGFR signaling in various cancer cell lines expressing FGFR1, FGFR2, and FGFR3.
Technical Note
AlphaLISA Acetyl‑Histone H3 lysine 27 (H3K27ac) cellular detection kit
This AlphaLISA immunodetection assay detects alterations in acetylated histone H3 lysine 27 (H3K27ac) levels within cellular extracts.
Application Note
Characterizing chemokine receptor inhibitors with AlphaLISA SureFire Ultra, Alpha SureFire Ultra Multiplex and LANCE Ultra cAMP assays
This application note demonstrates how the SureFire Ultra and LANCE Ultra cAMP assays can be used for measuring inhibitors to CCR7 and CXCR2 cell surface receptors using a cellular model system where these receptors are overexpressed in CHO cells.
Whitepaper
Shifting the treatment paradigm: the promise of gene therapy for neurodegenerative diseases
Traditional treatments for neurodegenerative diseases focus on managing symptoms, but recent advancements in gene therapy offer hope for more effective and sustainable solutions. Read now!
Whitepaper
Targeted protein degradation: A novel therapeutic strategy for neurodegenerative diseases
In this white paper, get details about TPD that offers a novel strategy for neurodegenerative diseases by degrading disease-linked proteins, showing promise in preclinical studies.
Application Note
AlphaLISA SureFire Ultra: elucidating TREM2/DAP12 signaling in neuroinflammation
This application note explores how the AlphaLISA™ SureFire® Ultra™ technology reveals the intricacies of TREM2/DAP12 signaling in neuroinflammation.
Looking for technical documents?
Find the technical documents you need, ASAP, in our easy-to-search library.